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ABSTRACT 
Cushing’s syndrome is associated with a number of clinical manifestations and co-morbidities 
which may not resolve even after long-term remission leading to excessive mortality. This 
review summarizes the main manifestations of Cushing’s syndrome (active or in remission) 
with particular focus on data from recently published relevant literature. Obesity and 
metabolic alterations, hypertension and cardio/cerebrovascular complications, 
hypercoagulability/thromboembolism, neuropsychiatric, muscle/skeletal and immune 
consequences remain the most challenging. Cardiovascular consequences and 
immunosuppression determine the main causes of death in Cushing’s syndrome necessitating 
early intervention when possible.  
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INTRODUCTION 
Cushing’s syndrome (CS) is associated with a significant number of clinical manifestations 
reflecting the exposure of tissues to high cortisol levels, and contributing to the reported 
increased mortality of these patients [1-4]. In this short review, the main manifestations of CS 
will be described with particular focus on data from recently published relevant literature. 
 
MANIFESTATIONS 
 
1. Obesity and Metabolic Alterations 
Weight gain is the most frequently reported clinical finding in CS (up to 82%) [5]. Central fat 
distribution, facial plethora and dorsocervical fat pads (‘buffalo hump’) are characteristic 
features but with a relatively low specificity. Females with Cushing’s disease (CD) have 
higher total, visceral and trunk subcutaneous adipose tissue but similar intermuscular 
adiposity, despite lower skeletal mass compared with weight-matched controls; furthermore, 
visceral adiposity exceeds the subcutaneous compartment [6]. Decreased AMP-activated 
protein kinase (AMPK) activity with a consequent increase in the expression of the lipid-
synthesizing enzyme fatty acid synthase (FAS) by the glucocorticoid excess has been 
proposed as a pathogenetic mechanism for the increased visceral adipose tissue [7]. Following 
remission, weight, BMI, waist circumference and all fat depots decrease, and fat distribution 
improves [8].  
Patients with CD have increased leptin [9,10], resistin [11] and pro-inflammatory agents, such 
as tumor necrosis factor-a (TNF-α) and interleukin-6 (IL-6), C-reactive protein (CRP) and 
endothelin-1 [12] and low ghrelin levels [9]. Data for adiponectin are controversial [9,13]. 
These metabolic changes contribute to insulin resistance [8] and to a pro-atherogenic profile 
[14]. With remission, there is improvement but not normalization of these abnormalities 
[8,11,13].  
Dyslipidemia has been reported in about 36% of patients with CS [15]. Total and LDL 
cholesterol are higher in patients with Cushing’s of pituitary and adrenal origin compared 
with controls but decrease significantly one year after remission only in those with adrenal 
disease [16]. In a study of 15 patients with CD cured for 5 years, hypercholesterolemia 
persisted in 27% [17]. The pathogenesis of the dyslipidemia is multifactorial and includes 
direct and indirect cortisol actions on lipolysis, free fatty acid production and turnover, VLDL 
synthesis, as well as fatty accumulation in the liver [18]. 
Of patients with CS, 18.5-64% have impaired glucose metabolism, while 20-47% have frank 
diabetes [5,17,19,20]. Giordano et al. found that the prevalence of impaired glucose tolerance 
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and diabetes reduced significantly one year after remission in adrenal CS but not in CD [16], 
and Colao et al. reported impaired glucose tolerance and diabetes in 27% and 33%, 
respectively, of patients with CD in remission for 5 years [17]. Hypercortisolemia affects both 
β-cell function and insulin sensitivity [21]; age, family history of diabetes and defects in 
insulin secretion play an additional role [19]. The homeostasis model assessment for insulin 
resistance (HOMA-IR) score is significantly reduced in CD subjects in remission [8].  
 
2. Hypertension  
The prevalence of hypertension in CS is approximately 70% [5,20]. Giordano et al. found a 
significant reduction in the prevalence of hypertension one year after remission but only in 
those with adrenal Cushing’s and not in those with CD [16]. Colao et al. reported that systolic 
and diastolic blood pressure remained significantly elevated in 15 patients with CD in 
remission for 5 years compared with sex-, age- and BMI-matched controls [17].   
The pathogenesis of hypertension relates to increased mineralocorticoid activity, 
enhancement of the cardiovascular reactivity to vasoconstrictors, increased endothelin-1 
production, inhibition of vasodilator release, modulation of the renin–angiotensin–aldosterone 
system activity and up-regulation of the sympathetic nervous system [22,23]. 
 
3. Hypercoagulability-Thromboembolism  
Patients with CS have a prothrombotic phenotype attributed to various abnormalities of 
coagulation and fibrinolysis; shortened activated partial thromboplastin time (aPTT) [24-26], 
increased factor VIII, von Willebrand factor (vWF), fibrinogen and plasminogen activator 
inhibitor-1 (PAI-1) [24,25],  decreased fibrinolytic capacity [24,26] and increased α2-
antiplasmin [25]. Moreover, the endothelium-dependent flow-mediated vasodilatation is 
impaired and several humoral markers of endothelial dysfunction (as endothelin, 
homocysteine, vascular endothelial growth factor, osteoprotegerin and cell adhesion 
molecules) are elevated. These alterations, together with secondary polycythemia, may play 
an additional role in the pathogenesis of the “hyperviscosity syndrome” [27,28]. 
The prevalence of venous thromboembolism is high during active CS [29]. Van Zaane et al. 
reported rates of 3.4% in ACTH-dependent CS after pituitary surgery; this was 0% in non-
ACTH CS post-operatively [30]. In another series of 40 CS patients who underwent pituitary 
or adrenal surgery, 7.5% had a thromboembolic event compared with 0% of those with non-
ACTH-secreting pituitary adenomas who underwent transsphenoidal operation [25]. 
One year after remission, mean vWF, PAI-1, antithrombin III and α2-antiplasmin decrease 
significantly [25]. Kastelan et al. studied 18 patients with CS six months after remission and 
found lower levels of factors II, V, XI, XII, protein C, S, antithrombin, plasminogen and C1 
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inhibitor compared with preoperative values. Fibrinolytic and haemostatic markers were 
similar between cured patients and controls, apart from factor XII and protein C [31]. In 
another study, short-term biochemical remission induced by medical therapy did not 
normalize the hemostatic balance [32].  
 
4. Cardiovascular and cerebrovascular manifestations  
The adverse cardiovascular risk profile in CS [15] is attributed to metabolic and vascular 
aberrations, as well as to changes in cardiac structure and function.  Vascular events remain 
the main cause of mortality in CS [1-4], with hazard ratios of 3.6 for acute myocardial infarct 
and 2.1 for stroke in patients with CD [33]. ECG changes in active CD include longer QTc 
dispersion, independent of the presence of cardiovascular disease and hypertension, and 
shorter QTc-min [34]. Echocardiograms demonstrate left ventricular hypertrophy (LVH), 
concentric remodeling and diastolic and systolic dysfunction [34-36] possibly related to 
increased myocardial fibrosis [37]. Heart failure and dilated cardiomyopathy [38,39] may be 
the first manifestations of CS.  Non-diabetic patients with CS show decreased heart rate 
variability independently of their hypertensive status [40], and impaired sympathetic 
reactivity [41] which tends to normalize six months after cure. Increased stiffness and intima 
media thickness are observed at carotid [42] and aortic sites [43]. Coronary microvascular 
function assessed by coronary flow reserve was found reduced in 30% of newly diagnosed 
patients without symptoms of ischemic heart disease and in the absence of epicardial coronary 
artery lesions [44]. Hypercortisolemia also affects the vascular wall through specific receptors 
on smooth muscle and endothelial cells, and induces hypertrophic remodeling in small 
resistance arteries [45] independently of blood pressure levels.  
Remission of hypercortisolemia reduces but does not completely eliminate the cardiovascular 
complications. Colao et al. reported that 27% of patients with CD in remission for 5 years had 
persistently atherosclerotic plaques compared with only 3% of gender-, age-and BMI-
matched controls ([17].  Barahona et al. found persistence of coronary artery disease in 
women, as well as in the whole group of patients aged less than 45 years, despite being in 
remission for a mean time of 11 years [46]. In a study of 15 patients with CS in remission, 
regression of LVH and improvement of LV diastolic function were shown 
echocardiographically after a median follow up of 18 months, while LV systolic performance 
improved early in the first month [36]. On the other hand, Toja et al. found that hypertrophic 
remodeling was still somewhat more prevalent than in controls after one year in remission 
[35]. 
 
5. Neuropsychiatric manifestations  
6 
 
Hypercortisolemia is associated with depression, disrupted sleep and a wide range of 
cognitive impairments (derangement of memory, especially short term, irritability and 
decreased concentration) [47,48]. High anxiety levels and low externalizing behavior are 
common emotional disorders [49]. Smaller hippocampal volumes, as well as generalized 
brain atrophy have been described [47].  Functional MRI studies in patients with CD have 
demonstrated emotion processing difficulties and hyperactivity in frontal and subcortical 
regions, similar to major depressive disorders [50]. 
Following remission, hippocampal volumes increase and emotional and cognitive functions 
improve [47,51-55], but profound structural alterations in the brain remain and correlate with 
persisting depressive symptoms, anxiety, social phobia, apathy and cognitive failure. Proton 
magnetic resonance spectroscopy (1H-MRS) did not demonstrate differences in the 
hippocampal volume between subjects with active CS, cured CS and healthy controls, but 
verbal and visual memory was worse in both CS groups. Total and cortical gray matter 
volumes were decreased in CS patients indicating brain atrophy, but subcortical gray matter 
(which includes hippocampal volume) was reduced only in those with memory impairment 
[56].  1H-MRS detected decreased N-acetyl-aspartate concentrations indicating neuronal 
damage and an increase in glutamate and glutamine reflecting glial proliferation as a repair 
mechanism in cured CS patients [57]. 
Structural abnormalities (smaller grey matter volumes in the anterior cingulate cortex and 
higher volume in the left posterior lobe of the cerebellum) have been detected in a group of 
patients with CD with sustained psychological dysfunction after long-term remission [58]. 
Finally, an increased prevalence of psychopathology, maladaptive personality traits, subtle 
cognitive abnormalities and impairment of reflecting memory and executive functions have 
been identified in another group following long-term cure [59]. 
 
6. Gonadal dysfunction  
Menstrual irregularities have been reported in 56% of women mainly as a result of the 
suppression of hypercortisolemia on the hypothalamo-pituitary-gonadal function [60]; 47% of 
the patients reported reduced libido [5], while males may present with erectile dysfunction 
[61].  
Glucocorticoids affect gonadal function at multiple levels in hypothalamo-pituitary-gonadal 
axis: the hypothalamus (decrease the synthesis and release of GnRH), the pituitary gland 
(inhibit the synthesis and release of LH and FSH) and the testes/ovaries (modulate 
steroidogenesis and/or gametogenesis directly) [62]. 
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7. Cutaneous manifestations  
The classical cutaneous manifestations of CS include acne, purpura, cutaneous atrophy and 
purple striae on the abdomen, flanks and upper arms. The characteristic purple color of the 
striae results from the translucency of the skin rendering the underlying vascular structures 
more visible. Histologically, cutaneous atrophy is manifested by thinning of the epidermis 
and flattening of the dermoepidermal junction due to the glucocorticoid-mediated inhibition 
of type I and III collagen synthesis and the reduction of hyaluronic acid content of the skin 
[63,64]. 
Hyperpigmentation may also be seen in CD and is mediated by the action of ACTH on 
melanocyte-stimulating receptors; it is generalized, but also more obvious in areas exposed to 
sunlight, friction, or trauma. Scars forming after the elevation of ACTH levels can remain 
permanently pigmented, whereas those present prior to that may not be pigmented [63,64]. 
 
8. Myopathy  
Proximal myopathy has been reported in some 67% of patients with CS [5]. In a series of 10 
patients with CD, circulating muscle proteins were significantly lower and muscle fiber 
conduction was slower compared with healthy controls [65]. 
 
9. Skeletal manifestations   
Osteopenia and osteoporosis in the spine have been reported in 41% and 23%, and in the hip 
in 50% and 12% of patients, respectively. Plain radiology has demonstrated vertebral 
fractures in 41% and hip fractures in 5% in one series [5]. Bone loss is attributed to decreased 
osteoblastic activity, increased osteoclastic bone resorption and impaired enteral calcium 
absorption. Furthermore, hypercortisolism impairs osteoblastic cell differentiation by 
inhibiting the Wnt signaling. Belaya et al. evaluated the presence of Wnt signaling 
antagonists and found higher levels of serum sclerostin in CS patients compared with healthy 
controls [66]. Thioredoxin interacting protein-1 (TXNIP) expression (major regulator of 
osteoblast mediated osteoclastogenesis) in bone biopsies from CS patients was significantly 
down-regulated following surgery [67]. 
Bone mineral density (BMD) does not completely recover following remission [68,69], 
although normalization at some skeletal sites has been reported after a prolonged period [70]. 
In a study with median follow up of 7 years, improvement in BMD was observed in 100% of 
patients in the spine and in 82% in the femur, although 73% of them had still femoral and 
vertebral T-scores in the range of osteopenia/osteoporosis [71]. Avascular necrosis of the 
femoral head is a rare complication [72].  
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10. Visual disorders  
Bilateral atypical central serous chorio-retinopathy and exophthalmos are rare complications 
[73,74].  Orbital fat volume is increased in CS patients, but in contrast to Graves’ disease, 
there is no infiltration by inflammatory cells, while the orbital muscles are relatively spared 
[74]. 
 
11. Quality of life  
The quality of life is significantly impaired in patients with active CS [5] and in those on 
long-term remission, regardless of etiology, presence of hormonal deficiencies or treatment 
strategies [75,76]. CS patients report more negative illness perceptions compared with 
patients with other acute or chronic conditions [77]. 
 
12. Immune system  
Hypercortisolism induces reversible immunosuppression. During active CS, autoimmune 
disorders improve but, during remission, they may worsen and new ones may develop 
[78,79]. There is a high risk of superficial fungal, opportunistic (Cryptococcus Neoformans, 
Candida and Norcardia species, Trichophyton Rubrum) or bacterial infections [80,81]. 
Corticosteroid excess induces cellular immune deficiency, lymphopenia and reduced ratio of 
CD4/CD8 and may affect IL-10-secreting regulatory T cells.  By inhibiting activation of 
nuclear factor κ ß, glucocorticoids interfere with the production of a number of cytokines, 
including IL-6, which play an integral role in mounting a response to bacterial infections 
[78,82]. 
 
13. Nephrolithiasis  
Nephrolithiasis is a common complication in active CD and persists even after remission [83]. 
Systemic arterial hypertension and an excess urinary excretion of uric acid may play a 
significant role in kidney stone formation.  
 
14. Manifestations in children  
Obesity, facial plethora and decreasing growth velocity are well documented features of CD 
in childhood and adolescence [84]. Pubertal delay or arrest are frequent and caused by 
suppression of the hypothalamic–pituitary–gonadal axis [85]. Premature sexual development 
may also occur due to increased secretion of androgens. Mental changes, sleep disturbances 
and muscle weakness are not as common as in adults, and school performance, in contrast to 
job performance in adults, is often satisfactory. Children and adolescents experience 
compromised final height, abnormal body composition, hypertension and impaired quality of 
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life after successful treatment of CS [86]. However, it has been the experience of many that 
there is a greater resolution of symptomatology in children compared to adults.  
 
CONCLUSIONS 
 
CS is associated with significant clinical manifestations affecting long-term morbidity, 
mortality and quality of life. Obesity and metabolic alterations, hypertension and 
cardio/cerebrovascular complications, hypercoagulability/thromboembolism, 
neuropsychiatric, muscle/skeletal and immune consequences remain the most challenging. To 
some extent, the duration and severity of hypercortisolism determine the possibility of 
reversion of the morbidities; however, a number of manifestations may persist long after cure 
and possibly permanently. Cardiovascular consequences and immunosuppression determine 
the main causes of death in CS necessitating early intervention when possible.  
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